Status:
COMPLETED
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
13-17 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
Eligibility Criteria
Inclusion
- Patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures
- Patient has a documented clinical diagnosis of schizophrenia
- Patient's parent or legal guardian will be able to accompany the patient at each scheduled study visit
Exclusion
- Patients (female) must not be pregnant or lactating
- Patients with a known intolerance or lack of response to previous treatment with quetiapine
- Patients who have previously participated in this study
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT00090324
Start Date
September 1 2004
End Date
June 1 2007
Last Update
January 4 2013
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Dothan, Alabama, United States
2
Research Site
Cerritos, California, United States
3
Research Site
Riverside, California, United States
4
Research Site
Sacramento, California, United States